STAA

Current Thesis

Post-merger-break special situation, not a momentum-narrative leg. STAAR makes the EVO/EVO+ ICL (Implantable Collamer Lens) — an implantable myopia-correction lens, refractive-surgery alternative to LASIK, heavily China-levered. Alcon agreed to buy STAAR at $28 (Aug 2025), bumped to $30.75 (74% premium to 90-day VWAP), but shareholders rejected it at the Jan 6 2026 special meeting; deal terminated, CEO Farrell and Chair Yeu pushed out. Broadwood Partners (31% holder) led the revolt, took board seats, and argues a standalone path to ~$50. The standalone story is genuinely inflecting — Q1 2026 (reported May 13) revenue $93.5M +120% YoY, non-GAAP EPS $0.29 vs $0.08 consensus, swung from a $54.2M loss to $5.2M net income on China EVO+ uptake. BUT the tape already faded from the $35.87 52-wk high / $32.01 (May 14) to ~$29 (Jun 4), avg sell-side PT is ~$29.67 (≈ spot, i.e. no momentum juice), and the live driver is the June 18 standstill expiry + annual meeting, an event-binary, not an accelerating narrative. This is a LOW-conviction probe at best — outside the core narrative-velocity edge.

Bull Case

• Q1 2026 (May 13): rev $93.5M, +120% YoY; non-GAAP EPS $0.29 crushed $0.08 consensus; net income swung +$5.2M from a -$54.2M loss a year prior. China EVO+ adoption is the driver — real demand recovery off the 2025 destocking collapse.
• Activist floor: Broadwood owns ~31% and keeps buying — Q1 2026 ~$21M (1.1M shares, filed May 14), plus discrete 2026 buys of $41M, $8.8M, $606k. A 31% holder accumulating into strength is a hard conviction signal, not a hope trade.
• M&A optionality re-arms June 18 2026 — Broadwood's standstill (no special-meeting demand) expires that day; same date as the annual meeting. Post-expiry the activist can push a renewed sale process. Alcon wanted this asset twice; another strategic could re-approach above $30.75. Broadwood publicly floated a $50/share standalone/sale path; Wedbush reiterated Outperform, $40 PT (May 29 2026).
• Tariff overhang being engineered away — management guided (May 13 call) to supply all China EVO/EVO+ from Switzerland by end-2026, removing US-tariff exposure on the China book.

Bear Case

• The momentum is already gone. Faded from [entry redacted] (52-wk high) and $32.01 (May 14) to ~$29 (Jun 4). Consensus PT ~$29.67 sits at spot — the $40 (Wedbush)/$50 (Broadwood) upside is entirely M&A/activist-contingent, not organic. If June 18 passes quietly, that premium deflates.
• China concentration is a flashing light. Q1: China distributors = 51% of net sales but 57% of trade receivables — receivables share running ahead of revenue share screams channel/collectability risk and possible sell-in pull-forward. This exact dynamic (China ICL destocking) took the stock to a $15.59 low in 2025.
• +120% YoY is a base effect, not a new secular ramp — it laps a collapsed Q1 2025. Sequential durability is unproven; the next print (~early Aug) is the real tell.
• Beginner trap = anchoring to the dead $30.75 deal / Broadwood's $50. "It'll get bought again" is a thesis, not a setup. No binding bid exists today.

Setup & Price Structure

• Spot ~$29.10 (Jun 4 2026, +3% intraday). 52-wk range $15.59–$35.87. Market cap ~$1.45B.
• Structurally mid-range and rolling over, not stretched and not blown off: below the May $32–$35.87 shelf, holding above the ~$26 post-Q1 consolidation / rising-200-day zone. RSI neutral — no overbought trim signal, no fresh breakout either.
• Sell-side dispersion IS the setup: consensus ~$29.67 (fair-value-now) vs Wedbush $40 vs Broadwood $50 — the gap is the event premium.
• For a momentum book this is MATURING: recovery is largely priced, tape has faded, only an event (June 18) or a clean higher-low reclaim of $32 re-arms a trade. Not a fresh-entry fat pitch.

Catalyst Calendar (next 30 days)

• 2026-06-18 — Broadwood standstill expiry + 2026 annual meeting (BINARY/PRIMARY). Vote on 7 directors, +3.9M equity-plan shares, BDO ratification, say-on-pay. Post-expiry Broadwood (31%) can agitate / push a renewed sale process. Watch for any strategic-review or sale-process language.
• ~Early Aug 2026 (est.) — Q2 2026 print (outside 30d; confirm exact date on investors.staar.com). The real test of China sequential durability and receivables quality. NOT an earnings-blackout name right now.
• No FDA/PDUFA in the 30-day window.

What Would Change Our Mind

• Upgrade to MEDIUM/HIGH only on: (a) a renewed binding takeover bid >$30.75, or (b) June 18 produces a formal strategic-review/sale-process announcement, or (c) a clean weekly higher-low reclaim of $32 on volume — confirmation that the standalone re-rate is back in gear.
• Invalidate / stand down on: weekly close below ~$26 (rising 200-day / consolidation floor); OR June 18 passes with no renewed sale-process and STAA loses $28 — event premium gone; OR Q2 China revenue declines sequentially with receivables rising (destocking redux).
• Not currently held → no trim rules active. If entered as a LOW probe, hard stop on a weekly a daily close below the thesis-invalidation level; trim/exit into any pop > $40 (the activist-bid zone) since upside above that is pure takeout speculation.

Correlation Notes

• Theme is ophthalmic medtech / refractive surgery + China-consumer recovery — NOT biotech-precision-therapeutics (prior dossier mis-tag; corrected). Peers/reads: Alcon (ALC) as the spurned acquirer and category bellwether; LASIK/refractive demand proxies. China-consumer-discretionary recovery tape is a co-driver given 51% China sales.
• This is primarily an idiosyncratic event-driven name — beta to broad AI/momentum themes is low. Its swing factor is the activist/M&A clock (June 18) and China demand, not market narrative velocity. Do not size it as if it correlates with the rest of a momentum book; it trades on its own catalyst path.

Beginner-Trap Check

• Peak retail sentiment? No — institutional/activist (Broadwood), not WSB squeeze.
• Stretched above MA? No — faded below recent highs, mid-range.
• Earnings <3d? No — Q1 done May 13; Q2 ~early Aug.
• Averaging-down trap? The live trap is anchoring to the dead $30.75 deal / Broadwood's $50 target. No bid exists today; trade the setup, not the memory.

Notes

• Source dates: Q1 print May 13 2026; Wedbush $40 reiterate May 29 2026; spot/price Jun 4 2026; Alcon deal terminated post-Jan 6 2026 vote; Broadwood cooperation agreement / board seats Jan 14–15 2026; standstill expiry + annual meeting Jun 18 2026.

Correlation Notes

(See above — ophthalmic medtech / China-recovery / event-driven; low correlation to AI-momentum book.)